Razumab – the role of biosimilars for the treatment of retinal diseases.

• L. Ferro Desideri ^{[1] [2]} ; C.A. Cutolo ^{[1] [2]} ; C.E. Traverso ^{[1] [2]} ; M. Nicolò ^{[1] [2] [3]}
  1. [1] University Eye Clinic of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  2. [2] Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), Universityof Genoa, Genoa, Italy
  3. [3] Macula Onlus Foundation, Genoa, Italy

  Mostrar afiliaciones +
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 8, 2021, págs. 499-505
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Biologics targeting vascular endothelial growth factor (anti-VEGF) are the mainstay treatment of many vascular retinal pathologies. To date, Razumab is the only approved biosimilar for ophthalmic use. Razumab showed no differences compared to the innovator ranibizumab, in terms of VEGF binding activity nor in inhibition of VEGF-induced proliferation. Clinical and preclinical studies have shown a favorable efficacy and safety profile of Razumab. Nonetheless, even if clinical equivalence is expected, randomized controlled clinical trials are needed to directly compare Razumab with the innovator ranibizumab in different retinal diseases.